Determination of Amigo2 targeting preventive agents for liver metastasis

Research Project

Project/Area Number	18K15125
Research Category	Grant-in-Aid for Early-Career Scientists
Allocation Type	Multi-year Fund
Review Section	Basic Section 49030:Experimental pathology-related
Research Institution	National Cancer Center Japan
Principal Investigator	Kanda Yusuke 国立研究開発法人国立がん研究センター, 研究所, 特任研究員(シニア・リサーチフェロー) (80803949)
Project Period (FY)	2018-04-01 – 2020-03-31
Project Status	Completed (Fiscal Year 2019)
Budget Amount *help	¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000) Fiscal Year 2019: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000) Fiscal Year 2018: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Keywords	肝転移予防 / Amigo2 / 化合物スクリーニング
Outline of Final Research Achievements	Development of preventive drugs for metastasis is expected to improve the prognosis of cancer patients. Previously, we identified Amigo2 as a driver gene involved in liver metastasis. Based on the idea that the signaling pathway-inhibitors required for Amigo2 expression may prevent liver metastasis, we evaluated the preventive effect of six kinds of Amigo2 inhibitors, which were found in our previous study, on liver metastasis. Each inhibitor decreased the metastasis. These results suggest that signaling molecule inhibitors, which decrease Amigo2 expression, could prevent liver metastasis.
Academic Significance and Societal Importance of the Research Achievements	肝転移予防薬の開発は、がん患者の予後を改善する上で重要な課題である。本研究で得られた成果は、Amigo2発現を抑制する複数種類のシグナル分子阻害剤が肝転移を抑制することを見出したものであり、既に承認済みの分子標的薬を活用したドラッグリポジショニングによる臨床応用への展開が期待される。